Lymphoma Classification and Pathology

Understanding lymphoma classification is not just an academic exercise; it is foundational to clinical oncology. Lymphomas, cancers of the lymphatic system, are broadly categorized into two major groups with distinct behaviors, treatments, and prognoses. Mastering their pathological hallmarks—from specific genetic translocations to unique cellular appearances—enables you to predict disease course, select targeted therapies, and communicate effectively within a multidisciplinary care team. This knowledge directly translates from the pathology slide to the patient's bedside.

The Fundamental Dichotomy: Hodgkin vs. Non-Hodgkin Lymphoma

The first and most critical distinction in lymphoma pathology is between Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL). This split is based on the presence or absence of a specific, pathognomonic malignant cell. HL is characterized by the Reed-Sternberg cell, a large, abnormal lymphocyte with a distinctive "owl's eye" appearance due to its bilobed nucleus and prominent nucleoli. Crucially, in HL, these malignant cells are vastly outnumbered by reactive inflammatory cells (lymphocytes, eosinophils, histiocytes) that form the tumor microenvironment.

In contrast, NHL encompasses all other lymphoid malignancies where the tumor bulk is primarily composed of the malignant lymphoid cells themselves. Beyond cellular composition, the spread pattern differs significantly. HL typically spreads in a predictable, orderly nodal spread pattern, moving contiguously from one lymph node group to an adjacent one. NHL, however, often exhibits non-contiguous, hematogenous (through the blood) spread, leading to more unpredictable involvement of distant nodes and extranodal sites like the gastrointestinal tract or central nervous system.

Key Subtypes of Non-Hodgkin Lymphoma (NHL)

NHL is a heterogeneous category subdivided by cell of origin (B-cell vs. T-cell) and growth pattern. Several common B-cell NHLs are defined by specific genetic drivers.

Follicular lymphoma (FL) is a common indolent (slow-growing) NHL. Its pathological signature is a translocation between chromosomes 14 and 18, written as t(14;18). This genetic mishap places the BCL2 gene next to a powerful promoter from the immunoglobulin heavy chain gene. The result is overexpression of the BCL-2 protein, which inhibits programmed cell death (apoptosis), allowing the lymphoma cells to survive abnormally long. Morphologically, the lymph node architecture is effaced by neoplastic follicles.

Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive NHL. As the name implies, it consists of large B-cells that grow in a diffuse pattern, completely overrunning the normal lymph node structure. It is a diagnosis of exclusion after other specific subtypes are ruled out. DLBCL is clinically heterogeneous, with some cases linked to prior Epstein-Barr virus (EBV) infection, particularly in older adults or immunocompromised patients.

Burkitt lymphoma is a highly aggressive B-cell NHL with one of the fastest doubling times of any human cancer. Its defining genetic lesion is a translocation involving the c-MYC gene, most commonly t(8;14). This translocation drives uncontrolled cellular proliferation. Burkitt lymphoma has a strong epidemiological association with EBV, especially in its endemic African form, which often presents as a jaw or abdominal mass. The classic "starry sky" appearance on pathology is created by numerous benign macrophages (the "stars") scattered among sheets of darkly staining malignant lymphocytes (the "sky").

Clinical Correlates: Staging and Systemic Symptoms

Pathology informs clinical staging, which is crucial for treatment planning. The Ann Arbor staging system is the classic framework used for both HL and NHL. Its significance lies in defining the anatomic extent of disease:

• Stage I: Involvement of a single lymph node region.
• Stage II: Involvement of two or more lymph node regions on the same side of the diaphragm.
• Stage III: Involvement of lymph node regions on both sides of the diaphragm.
• Stage IV: Diffuse or disseminated involvement of one or more extralymphatic organs (e.g., bone marrow, liver).

Each stage is also modified by the absence (A) or presence (B) of systemic symptoms. B symptoms refer to a specific triad: unexplained fever (above 38°C / 100.4°F), drenching night sweats, and unexplained weight loss exceeding 10% of body weight within six months. The presence of "B" symptoms often indicates more advanced or aggressive disease and influences therapy decisions.

Common Pitfalls

1. Confusing Reed-Sternberg cells with reactive immunoblasts: Inexperienced observers may mistake large, reactive lymphocytes in infections for malignant Reed-Sternberg cells. The key is to look for the classic bilobed "mirror-image" nucleus with huge inclusion-like nucleoli. The context of scarce malignant cells amidst a reactive background is also a critical clue for HL.
2. Overlooking the importance of genetic studies in NHL: Relying solely on histology (what is seen under the microscope) can lead to misclassification. For example, not all aggressive B-cell lymphomas with a "starry sky" pattern are Burkitt lymphoma; some may be high-grade DLBCL. Fluorescence in situ hybridization (FISH) testing for translocations like c-MYC, BCL2, and BCL6 is essential for precise diagnosis and prognosis.
3. Misapplying the Ann Arbor staging system: It is a mistake to assume Ann Arbor staging applies identically to all NHL subtypes. While useful for HL and many nodal NHLs, it has less relevance for certain extranodal NHLs (like primary gastric lymphoma) or leukemic presentations, which may use different staging systems.
4. Assuming "B symptoms" are generic: Labeling any fatigue or mild night dampness as a "B symptom" dilutes its prognostic value. Strict adherence to the defined criteria—high fever, drenching sweats requiring bedding change, and significant documented weight loss—is necessary for accurate clinical assessment.

Summary

• Lymphomas are primarily classified as Hodgkin Lymphoma (HL), defined by Reed-Sternberg cells and orderly spread, or Non-Hodgkin Lymphoma (NHL), a diverse group with non-contiguous spread.
• Key NHL subtypes are defined by specific genetic lesions: Follicular lymphoma by the t(14;18) BCL2 translocation, and Burkitt lymphoma by a c-MYC translocation and a strong EBV association.
• Diffuse large B-cell lymphoma (DLBCL) is a common aggressive NHL diagnosed by morphology after excluding other types, with some cases also linked to EBV.
• The Ann Arbor staging system categorizes disease extent (Stages I-IV), modified by the presence or absence of constitutional B symptoms (fever, night sweats, weight loss), which are critical for treatment planning.
• Accurate diagnosis integrates histology, immunohistochemistry, and genetic studies to avoid pitfalls and guide targeted, effective therapy.